130 related articles for article (PubMed ID: 26034219)
1. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
3. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Agulnik M
Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
[TBL] [Abstract][Full Text] [Related]
4. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI; Ott PA; Ferris RL; Cascone T; Schadendorf D; Le DT; Sharma MR; Barlesi F; Sharfman W; Luke JJ; Melero I; Lathers D; Neely J; Suryawanshi S; Sanyal A; Holloway JL; Suryawanshi R; Ely S; Segal NH
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458639
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP; Alonso-Gordoa T; Banerjee S; Wang D; Naidoo J; Standifer NE; Palmer DC; Cheng LY; Kourtesis P; Ascierto ML; Das M; Diamond JR; Hellmann MD; Carneiro BA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309722
[TBL] [Abstract][Full Text] [Related]
6. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz MA; Landau H; Comenzo RL; Seldin D; Weiss B; Zonder J; Merlini G; Schönland S; Walling J; Kinney GG; Koller M; Schenk DB; Guthrie SD; Liedtke M
J Clin Oncol; 2016 Apr; 34(10):1097-103. PubMed ID: 26858336
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with CD64-directed immunotherapy. An overview.
Curnow RT
Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
[TBL] [Abstract][Full Text] [Related]
9. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.
Mehra R; Serebriiskii IG; Dunbrack RL; Robinson MK; Burtness B; Golemis EA
Drug Resist Updat; 2011 Dec; 14(6):260-79. PubMed ID: 21920801
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Bokemeyer C; Ciardiello F; Dubreuil O; Guigay J; Kasper S; Pfeiffer P; Pinto C; Yamaguchi K; Yoshino T; Zielinski C; Esser R; Tabernero J
Future Oncol; 2024 Mar; 20(7):393-407. PubMed ID: 37850363
[TBL] [Abstract][Full Text] [Related]
11. A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.
Cohn A; Lahn MM; Williams KE; Cleverly AL; Pitou C; Kadam SK; Farmen MW; Desaiah D; Raju R; Conkling P; Richards D
Int J Oncol; 2014 Dec; 45(6):2221-31. PubMed ID: 25270361
[TBL] [Abstract][Full Text] [Related]
12. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Segal NH; Melero I; Moreno V; Steeghs N; Marabelle A; Rohrberg K; Rodriguez-Ruiz ME; Eder JP; Eng C; Manji GA; Waterkamp D; Leutgeb B; Bouseida S; Flinn N; Das Thakur M; Elze MC; Koeppen H; Jamois C; Martin-Facklam M; Lieu CH; Calvo E; Paz-Ares L; Tabernero J; Argilés G
Nat Commun; 2024 May; 15(1):4091. PubMed ID: 38750034
[TBL] [Abstract][Full Text] [Related]
13. Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Yu T; Liu X; Wu CY; Tang Z; Wang H; Schnell P; Wan Y; Wang K; Liu L; Gao Y; Sahasranaman S; Budha N
Clin Transl Sci; 2024 Mar; 17(3):e13769. PubMed ID: 38515348
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
16. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
Mancini M; Gaborit N; Lindzen M; Salame TM; Dall'Ora M; Sevilla-Sharon M; Abdul-Hai A; Downward J; Yarden Y
Sci Signal; 2015 Jun; 8(379):ra53. PubMed ID: 26038598
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.
Bhardwaj B; Revannasiddaiah S; Bhardwaj H; Balusu S; Shwaiki A
Ann Transl Med; 2016 Feb; 4(3):50. PubMed ID: 26904572
[TBL] [Abstract][Full Text] [Related]
18. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Dey N; Williams C; Leyland-Jones B; De P
Am J Transl Res; 2015; 7(4):733-50. PubMed ID: 26064441
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP
J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183
[TBL] [Abstract][Full Text] [Related]
20. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
